Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs


New Study: HIV/AIDS Most Prevalent Among Africa's "Richest"

In a controversial new study presented at the ongoing PEPFAR conference in Durban and reported in Wednesday's Boston Globe, researchers at ORC Macro have concluded that wealthy people (the top quintile) in Africa are infected with HIV/AIDS at higher rates than poorer people. These finding contradict widely held beliefs and undermine the notion that poverty is a main driver of AIDS.

IDPF-UNITAID: A "New" Economic Model?

I've said it before, and I'll say it again: increasing demand raises prices. And yet the Joint Declaration on the International Drug Purchase Facility - UNITAID issued by Brazil, Chile, France and Norway at the launch of UNITAID on June 2nd explicitly includes the following contradictory principles of the new entity:

Gates Funds New HPV Vaccine Program at PATH

On June 5th, the Bill & Melinda Gates Foundation announced a five-year, $27.8 million grant to PATH for program research in India, Peru, Uganda, and Vietnam intended to inform country decisions about HPV vaccine introduction to prevent cervical cancer. PATH will help plan for and pilot introduction in the four countries, with the goal of informing regional and global vaccine introduction efforts and international financing plans.

Innovation and public health

The World Health Assembly (the governing body of the WHO) has agreed to launch a working group on research and development, to promote R&D aimed at diseases that disproportionately affect developing countries. The decision represents a compromise between two apparently contradictory positions.

The new resolution (A59/A/Conf. Paper No 8) encourages member states:

The End of AIDS: All About the Money?

According to today’s New York Times, UNAIDS officials have estimated that stopping the HIV/AIDS pandemic will require $22 billion annually by 2008, and perhaps more in subsequent years. Of this $22 billion, $11 billion will be needed for prevention efforts, and $5.5 billion for care and treatment of infected people, with the rest used to support program costs and efforts to support orphans and vulnerable children.